Prosecution Insights
Prosecution Insights
13 pending office actions • 8 art units • 11 examiners • 1 of 13 (8%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (8%) |
| §112 only | 3 (23%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 3 (23%) |
| Multi-statute (no §101) | 5 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 3 | 61.0% | +83.7% |
| FAUST, AMBER KATHLEEN | 1 | 60.9% | +52.1% |
| O'NEILL, MARISOL ANN | 1 | 54.8% | +63.6% |
| HOPKINS, SAMANTHA LAKE | 1 | 55.3% | +63.4% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.7% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.7% | +36.9% |
| TAKENAKA, RISA | 1 | 28.6% | +100.0% |
| NATARAJAN, MEERA | 1 | 62.3% | +17.6% |
| MATALKAH, FATIMAH KHALAF | 1 | 55.3% | +28.5% |
| DHAR, MATASHA | 1 | 43.8% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040951 | ENGINEERED IMMUNE EFFECTOR CELLS AND USE THEREOF | DHAR, MATASHA | 44d overdue |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | — |
| 18250735 | ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL | HOPKINS, SAMANTHA LAKE | — |
| 18246174 | IMPROVED REPROGRAMMING, MAINTENANCE AND PRESERVATION FOR INDUCED PLURIPOTENT STEM CELLS | TAKENAKA, RISA | — |
| 17627574 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | NATARAJAN, MEERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040951 | ENGINEERED IMMUNE EFFECTOR CELLS AND USE THEREOF | DHAR, MATASHA | 44d overdue |
| 18917836 | EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS | FAUST, AMBER KATHLEEN | — |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | — |
| 18501627 | COMPOSITION AND METHODS FOR INDUCING MYELOID SUPPRESSIVE CELLS AND USE THEREOF | O'NEILL, MARISOL ANN | — |
| 18250735 | ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL | HOPKINS, SAMANTHA LAKE | — |
| 18250737 | MULTIPLEXED ENGINEERED IPSCS AND IMMUNE EFFECTOR CELLS TARGETING SOLID TUMORS | STOICA, ELLY GERALD | — |
| 18250733 | ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS | SZPERKA, MICHAEL EDWARD | — |
| 18246174 | IMPROVED REPROGRAMMING, MAINTENANCE AND PRESERVATION FOR INDUCED PLURIPOTENT STEM CELLS | TAKENAKA, RISA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1643 | 2 |
| 1641 | 2 |
| 1632 | 2 |
| 1633 | 1 |
| 1647 | 1 |
| 1638 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18917836 | EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS | FAUST, AMBER KATHLEEN | 1643 | §103 | Final Rejection | — | Pending | Oct 16, 2024 |
| 18441709 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | ZHU, JIANJIAN | 1631 | §102§103 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18501627 | COMPOSITION AND METHODS FOR INDUCING MYELOID SUPPRESSIVE CELLS AND USE THEREOF | O'NEILL, MARISOL ANN | 1633 | §112Other | Final Rejection | — | Pending | Nov 03, 2023 |
| 18250735 | ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL | HOPKINS, SAMANTHA LAKE | 1641 | §102§103§112 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18250737 | MULTIPLEXED ENGINEERED IPSCS AND IMMUNE EFFECTOR CELLS TARGETING SOLID TUMORS | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18250733 | ENGINEERED IPSC AND PERSISTENT IMMUNE EFFECTOR CELLS | SZPERKA, MICHAEL EDWARD | 1641 | DP | Non-Final OA | — | Pending | Apr 26, 2023 |
| 18246174 | IMPROVED REPROGRAMMING, MAINTENANCE AND PRESERVATION FOR INDUCED PLURIPOTENT STEM CELLS | TAKENAKA, RISA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Mar 21, 2023 |
| 17627574 | IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | NATARAJAN, MEERA | 1643 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2022 |
| 17769651 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | 1631 | §103DP | Final Rejection | — | Pending | Apr 15, 2022 |
| 17766513 | ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF | ZHU, JIANJIAN | 1631 | §103DPOther | Final Rejection | — | Pending | Apr 04, 2022 |
| 17762693 | MULTI-TARGETING EFFECTOR CELLS AND USE THEREOF | MATALKAH, FATIMAH KHALAF | 1638 | §103DP | Non-Final OA | — | Pending | Mar 22, 2022 |
| 17040951 | ENGINEERED IMMUNE EFFECTOR CELLS AND USE THEREOF | DHAR, MATASHA | 1632 | §103§112 | Non-Final OA | 44d overdue | AI Ready | Sep 23, 2020 |
| 16765369 | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS | GAO, ASHLEY HARTMAN | 1678 | §112Other | Non-Final OA | — | Pending | May 19, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial